Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lim

Showing results (451-460 of 468) with videos related to

Pageof 47
Sort By:
Neuro-Oncology Advances|May 19, 2021
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessmentMaciej M Mrugala, Quinn T Ostrom, Shelley M Pressley, et al.
Immunity|August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial functionChristopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
Nature Medicine|July 24, 2023
Correcting the drug development paradigm for glioblastoma requires serial tissue samplingKirit Singh, Kelly M Hotchkiss, Ian F Parney, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAMAlexander H Pearlman, Yuxuan Wang, Anita Kalluri, et al.
Genome Biology|August 28, 2020
Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastomaJason K Sa, Nakho Chang, Hye Won Lee, et al.
Neuro-Oncology|December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think TankPavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
Cell Reports. Medicine|August 8, 2023
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluidChristopher Douville, Samuel Curtis, Mahmoud Summers, et al.
Pageof 47

Showing results (451-460 of 468) with videos related to

Sort By:
Pageof 47
Neuro-Oncology Advances|May 19, 2021
The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessmentMaciej M Mrugala, Quinn T Ostrom, Shelley M Pressley, et al.
Immunity|August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8<sup>+</sup> T cell responses by disrupting mitochondrial functionChristopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
Nature Medicine|July 24, 2023
Correcting the drug development paradigm for glioblastoma requires serial tissue samplingKirit Singh, Kelly M Hotchkiss, Ian F Parney, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2024
Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAMAlexander H Pearlman, Yuxuan Wang, Anita Kalluri, et al.
Genome Biology|August 28, 2020
Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastomaJason K Sa, Nakho Chang, Hye Won Lee, et al.
Neuro-Oncology|December 28, 2020
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think TankPavlina Chuntova, Frances Chow, Payal B Watchmaker, et al.
Cell Reports. Medicine|August 8, 2023
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluidChristopher Douville, Samuel Curtis, Mahmoud Summers, et al.
Pageof 47